UNSPSC 51381502: Etofenamate

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C18H18F3NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KZF0XM66JC, chemically known as 2-(2-hydroxyethoxy)ethyl-n-(alpha,alpha,alpha-trifluoro-m-tolyl)anthranilate but generally known as etofenamate, which bears US NIH Compound Identifier 35375. European Medicines Agency schedules Etofenamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07319MIG.

UNSPSC 51381502 Etofenamate is a Commodity code that nominally identifies a single anti-inflammatory pharmaceutical product, but recent state and local procurement activity under this code shows minimal alignment with that specific agent. Instead, solicitations tagged to this code are acquiring a broad range of pharmaceuticals, over-the-counter products, and health-related systems including naloxone, drug deactivation equipment, and generic multi-source medications through competitive bidding and cooperative purchasing vehicles. The issuing bodies span state health and human services agencies, county health departments, and multistate cooperative purchasing alliances. The work involves managing pharmaceutical supply chains, establishing vendor relationships with wholesalers and manufacturers, and ensuring compliance with FDA requirements, cGMP standards, the Drug Supply Chain Security Act, and various federal and state regulatory frameworks around drug procurement and distribution.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: this deadline predates the posting date and reflects a data inconsistency in the source). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling exploratory interest in direct contracting models outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration, through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, requiring vendors to work through three authorized wholesalers and certify cGMP and DSCSA compliance with pricing weighted 75 percent of evaluation.